RE: Any observationsUnlike f3, I thought the point that none of the directors (except one), don't own any stock beyond the options awarded very interesting. If I were personally involved in a company that has very encouraging results regarding the cure of a major disease, I would be wanting as big of piece of the pie as I could get. The fact that the directors are privy to data that is unreleased and they don't extend their ownership position doesn't give me, as an investor, much confidence.
I also found it interesting that the projected burn rate is the same as the current burn rate ($600 K/month), even though we are moving into more costly Phase II trials. When asked how long the new trials would take, Brad wasn't entirely clear if they would be completed before the current cash on hand would be spent (23 months). I think as an investor we should be very concerned with financial data. The best clinical results don't mean much if the company doesn't have any money to proceed with production.
JMHO
Digory